logo-loader
HealthPharma & Biotech
viewShield Therapeutics PLC

Broad label approval is 'best possible outcome' for Shield Therapeutics' Feraccru

Proactive Research analyst Emma Ulker discusses what she describes as the best possible outcome for Shield Therapeutics PLC (LON:STX) and its lead drug Feraccru. 

The US Food & Drug Administration (FDA) has approved the treatment for a broad label to treat iron deficiency (ID) in adults, addressing a population many times wider than the iron deficiency anaemia (IDA) indications included in the submission data.

Quick facts: Shield Therapeutics PLC

Price: 181.5 GBX

LSE:STX
Market: LSE
Market Cap: £212.7 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: Analyst discusses further positive data from...

Proactive Research analyst Emma Ulker discusses further positive data which has been released from Shield Therapeutics' (LON:STX) non-inferiority AEGIS H2H study. It pitted Shield's oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) against intravenous ferric carboxymaltose...

1 week, 5 days ago

2 min read